Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Ottaviani

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Bioanalysis|January 24, 2017
An ultra-sensitive LC-MS/MS method to determine midazolam levels in human plasma: development, validation and application to a clinical studyMu Chen, Wenzhe Lu, Yang Lu, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2016
Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitorsHolger Kühne, Ulrike Obst-Sander, Bernd Kuhn, et al.
Nephron|December 10, 2015
Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic NephropathyCarlamaria Zoja, Monica Locatelli, Daniela Corna, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2010
Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitorsCarole Pissot-Soldermann, Marc Gerspacher, Pascal Furet, et al.
Journal of Medicinal Chemistry|September 26, 2015
Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus MonkeysRainer E Martin, Johannes D Aebi, Benoit Hornsperger, et al.
Chemmedchem|August 1, 2015
Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney DiseasesMatthias Nettekoven, Jean-Michel Adam, Stefanie Bendels, et al.
Journal of Medicinal Chemistry|October 6, 2023
Discovery of 4,5,6,7-Tetrahydropyrazolo[1.5-a]pyrizine Derivatives as Core Protein Allosteric Modulators (CpAMs) for the Inhibition of Hepatitis B VirusBuyu Kou, Zhisen Zhang, Xingchun Han, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 18, 2018
Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus InhibitorNicole A Kratochwil, Miriam Triyatni, Martina B Mueller, et al.
The EMBO Journal|June 8, 2018
NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALSNajwa Ouali Alami, Christine Schurr, Florian Olde Heuvel, et al.
Journal of Medicinal Chemistry|March 10, 2023
Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV InfectionWeixing Zhang, Lei Guo, Haixia Liu, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Bioanalysis|January 24, 2017
An ultra-sensitive LC-MS/MS method to determine midazolam levels in human plasma: development, validation and application to a clinical studyMu Chen, Wenzhe Lu, Yang Lu, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2016
Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitorsHolger Kühne, Ulrike Obst-Sander, Bernd Kuhn, et al.
Nephron|December 10, 2015
Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic NephropathyCarlamaria Zoja, Monica Locatelli, Daniela Corna, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2010
Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitorsCarole Pissot-Soldermann, Marc Gerspacher, Pascal Furet, et al.
Journal of Medicinal Chemistry|September 26, 2015
Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus MonkeysRainer E Martin, Johannes D Aebi, Benoit Hornsperger, et al.
Chemmedchem|August 1, 2015
Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney DiseasesMatthias Nettekoven, Jean-Michel Adam, Stefanie Bendels, et al.
Journal of Medicinal Chemistry|October 6, 2023
Discovery of 4,5,6,7-Tetrahydropyrazolo[1.5-a]pyrizine Derivatives as Core Protein Allosteric Modulators (CpAMs) for the Inhibition of Hepatitis B VirusBuyu Kou, Zhisen Zhang, Xingchun Han, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 18, 2018
Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus InhibitorNicole A Kratochwil, Miriam Triyatni, Martina B Mueller, et al.
The EMBO Journal|June 8, 2018
NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALSNajwa Ouali Alami, Christine Schurr, Florian Olde Heuvel, et al.
Journal of Medicinal Chemistry|March 10, 2023
Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV InfectionWeixing Zhang, Lei Guo, Haixia Liu, et al.
Pageof 3